Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DHA, ARA infant formulas

This article was originally published in The Tan Sheet

Executive Summary

FDA should require a warning on infant formulas that contain DHA and ARA from algal and fungal sources to alert parents of the potential for adverse reactions to the formulas, the Cornucopia Institute and the National Alliance for Breastfeeding Advocacy state in Jan. 24 comments to the agency. Labeling should state that the ingredients "have been linked to diarrhea, bloating, vomiting, and other gastrointestinal problems in some infants," the groups say. Additionally, labeling should instruct parents to "discontinue usage and seek medical help if your infant reacts adversely" and if "symptoms do not immediately [resolve] upon switching to [an] alternative formula without DHA/ARA oils," they add. The groups state that 98 adverse reaction reports submitted to FDA's MedWatch program can "reasonably be linked to DHA and ARA oils in infant formula" and say the scientific community disagrees about the benefits of the ingredients in infant formula. Failure to warn parents about these ingredients, they add, violates the Federal Food, Drug and Cosmetics Act...

You may also be interested in...



Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California

US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel